Table 5 A summary of clinical trials based on combination therapy with ICIs plus other modalities in human cancers registered in https://clinicaltrials.gov (October 2021)
From: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Condition | Agents | Study phase | Participant number | Study location | NCT number | |
|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | Platinum + Durvalumab | 2 | 55 | USA | NCT04062708 | |
Solid tumor Hematological malignancy | Eliglustat + ICI | 1 | 30 | China | NCT04944888 | |
Advanced tumors | Ipilimumab, Nivolumab, Pembrolizumab + BBI608 | 1/2 | 104 | USA | NCT02467361 | |
Non-small-cell lung carcinoma | Tocilizumab + Atezolizumab | 1/2 | 28 | USA | NCT04691817 | |
Non-small-cell lung carcinoma | Platinum + angiogenesis inhibitors and ICI | NA | 126 | China | NCT04137588 | |
Hepatocellular carcinoma Biliary tract cancer | Nivolumab + Pembrolizumab | NA | 100 | Republic of Korea | NCT03695952 | |
Pancreatic cancer | RT + ICI | 1/2 | 52 | USA | NCT04327986 | |
Advanced solid tumors | ASP8374 + Pembrolizumab | 1 | 169 | USA | NCT03260322 | |
Solid tumor Lymphoma | Ad-p53 Gene Therapy + ICI | 2 | 40 | USA | NCT03544723 | |
Multiple primary lung cancer | Microwave ablation + Camrelizumab | 2 | 146 | China | NCT05053802 | |
Advanced solid tumors | FT500 + ICI | 1 | 76 | USA | NCT03841110 | |
Advanced solid tumors | DSP-7888 Dosing Emulsion + ICI | 1/2 | 84 | USA | NCT03311334 | |
Intrahepatic cholangiocarcinoma | ICI + Lenvatinib and Sintilimab | 2 | 25 | China | NCT05010681 | |
Solid tumors | Gut Microbiome + ICI | NA | 800 | USA | NCT05037825 | |
Non-small-cell lung carcinoma | ICI + OSE2101, Docetaxel, Pemetrexed | 3 | 363 | USA | NCT02654587 | |
Genitourinary cancer Melanoma | Infliximab or Vedolizumab + ICI | 1/2 | 100 | USA | NCT04407247 | |
Non-small-cell lung carcinoma | Pembrolizumab + RT | 1/2 | 164 | International | NCT03996473 | |
Non-small-cell lung carcinoma | Ramucirumab + Atezolizumab | 2 | 21 | USA | NCT05007769 | |
Non-small-cell lung carcinoma | Ipilimumab + Nivolumab | 3 | 1360 | France | NCT03469960 | |
Renal cell carcinoma | Atezolizumab + Cabozantinib | 3 | 500 | International | NCT04338269 | |
Cervical cancer | BAVC-C + Durvalumab | 2 | 37 | Republic of Korea | NCT04800978 | |
Cervical cancer | Pembrolizumab + Platinum and RT | 1 | 1 | United Kingdom | NCT03144466 | |
Squamous cell carcinoma of head and neck | Nivolumab + Surgical resection | 2 | 24 | USA | NCT03878979 | |
Non-small-cell lung carcinoma | Atezolizumab + RT | 1 | 2 | USA | NCT02599454 | |
Advanced solid tumors | Nivolumab + Copanlisib | 1/2 | 102 | USA | NCT04317105 | |
Inoperable esophageal Cancer | Nivolumab, Ipilimumab + Chemoradiation | 2 | 103 | France | NCT03437200 | |
Non-small-cell lung carcinoma | Ramucirumab + SAR408701 | 2 | 36 | USA | NCT04394624 | |
Hepatocellular carcinoma | Pembrolizumab + Regorafenib | 2 | 119 | USA | NCT04696055 | |
Lung cancer | Pembrolizumab + Idelalisib | 1/2 | 40 | USA | NCT03257722 | |
Metastatic colorectal cancer | Atezolizumab + Bevacizumab and RT | 2 | 52 | France | NCT04659382 | |
Advanced solid cancers | Ipilimumab, Nivolumab + Copanlisib Hydrochloride | 1/2 | 102 | USA | NCT04317105 | |
Esophageal cancer | Nivolumab, Ipilimumab + Chemoradiation | 2 | 130 | France | NCT03437200 | |
Non-small-cell lung carcinoma | Ramucirumab + Atezolizumab | 2 | 21 | USA | NCT03689855 | |
Castration-resistant prostate cancer | Pembrolizumab + HER2Bi-armed | 2 | 33 | USA | NCT03406858 | |
Advanced solid tumors | ICI + RT | NA | 200 | Germany | NCT04892849 | |
Liver-dominant Metastatic colorectal cancer | Atezolizumab + RT, Bevacizumab | 2 | 52 | France | NCT04659382 | |